Literature DB >> 24084340

Pertussis immunisation and control in England and Wales, 1957 to 2012: a historical review.

G Amirthalingam1, S Gupta, H Campbell.   

Abstract

This review summarises the epidemiology and control of pertussis in England and Wales since the introduction of routine immunisation and considers the implications for future control. Routine infant immunisation with a whole-cell pertussis (wP) vaccine was introduced in 1957 and had a marked impact on the overall disease burden. Following a fall in vaccine coverage during the 1970s and 80s linked to a safety scare with wP vaccine, there was an extended period of high coverage and pertussis incidence fell dramatically. Incidence continued to decrease with the introduction of an acellular pertussis vaccine in the pre-school booster in November 2001 and in the primary United Kingdom (UK) schedule in September 2004 but has increased since July 2011. In response to a high rate of pertussis in infants, a temporary vaccination programme for pregnant women was introduced in October 2012. The key aim of the programme is to protect vulnerable infants from birth in the first months of life, before they can be fully protected by routine infant immunisation. A review of the UK adolescent immunisation programme is currently ongoing and the inclusion of a pertussis booster is being considered.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24084340     DOI: 10.2807/1560-7917.es2013.18.38.20587

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  39 in total

Review 1.  Strategies and new developments to control pertussis, an actual health problem.

Authors:  María Emilia Gaillard; Daniela Bottero; Griselda Moreno; Martin Rumbo; Daniela Hozbor
Journal:  Pathog Dis       Date:  2015-08-09       Impact factor: 3.166

2.  Universal tetanus, diphtheria, acellular pertussis (Tdap) vaccination of adults: What Canadian health care providers know and need to know.

Authors:  D MacDougall; B A Halperin; D MacKinnon-Cameron; L Li; S A McNeil; J M Langley; S A Halperin
Journal:  Hum Vaccin Immunother       Date:  2015-06-19       Impact factor: 3.452

Review 3.  The first steps towards the era of personalised vaccinology: predicting adverse reactions.

Authors:  P Pellegrino; F S Falvella; V Perrone; C Carnovale; T Brusadelli; M Pozzi; S Antoniazzi; S Cheli; C Perrotta; E Clementi; S Radice
Journal:  Pharmacogenomics J       Date:  2014-10-07       Impact factor: 3.550

4.  Polymorphism of IL-10 gene promoter region: association with T cell proliferative responses after acellular pertussis vaccination in adults.

Authors:  Kirsi Gröndahl-Yli-Hannuksela; Tero Vahlberg; Jorma Ilonen; Jussi Mertsola; Qiushui He
Journal:  Immunogenetics       Date:  2016-06-10       Impact factor: 2.846

Review 5.  Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.

Authors:  Dorji Dorji; Frits Mooi; Osvaldo Yantorno; Rajendar Deora; Ross M Graham; Trilochan K Mukkur
Journal:  Med Microbiol Immunol       Date:  2017-11-21       Impact factor: 3.402

6.  Improving vaccine coverage in adolescence and beyond.

Authors:  Michelle Falconer
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

Review 7.  The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.

Authors:  Pier Luigi Lopalco; Frank DeStefano
Journal:  Vaccine       Date:  2014-11-04       Impact factor: 3.641

Review 8.  Antenatal immunization.

Authors:  Chrissie Jones; Paul Heath
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Core pertussis transmission groups in England and Wales: A tale of two eras.

Authors:  Ana I Bento; Maria A Riolo; Yoon H Choi; Aaron A King; Pejman Rohani
Journal:  Vaccine       Date:  2018-02-01       Impact factor: 3.641

Review 10.  Pertussis: Microbiology, Disease, Treatment, and Prevention.

Authors:  Paul E Kilgore; Abdulbaset M Salim; Marcus J Zervos; Heinz-Josef Schmitt
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.